Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Iron Chelator" patented technology

Use of iron chelating agents in treatment of HSV-1 and VSV viral infections

PendingCN121868301AAntipyreticAnalgesicsDeferoxamine mesylateIron Chelator
The invention discloses application of an iron chelating agent in treatment of HSV-1 and VSV virus infection. By constructing a mouse model infected by HSV-1 and VSV viruses, it is verified that the iron chelating agent can significantly promote activation of an I-type interferon signal channel of a host after virus infection; virus replication in various tissues can be inhibited, and secretion of antiviral cell factors can be promoted; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows a consistent immunopotentiation effect in mouse and human immune cells; the iron chelating agent is selected from any one or a combination of more of deferoxamine mesylate, deferiprone and ciclopirox. The iron chelating agent provided by the invention does not depend on virus TK / DNApol, overcomes the defect of high drug resistance of traditional HSV-1 and VSV virus treatment drugs to a certain extent, and has good clinical application prospects and application values.
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT

Nucleic acids to inhibit TMPRSS6 expression and iron chelators

UndeterminedES3072798T3Iron ChelatorBeta thalassemia
The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with or inhibit the expression of the TMPRSS6 gene in combination with one or more iron chelators and possibly other active agents, as well as to therapeutic uses such as the treatment of hemochromatosis, porphyria, and blood disorders such as beta-thalassemia, sickle cell anemia, and transfusion iron overload or myelodysplastic syndrome, as well as infections and mortality not related to relapses associated with bone marrow transplantation.
Owner:SILENCE THERAPEUTICS GMBH (100 00)

CNS delivery of iron-chelators

Owner:YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD +1

A gallium-iron chelator composite nanohydrogel, a preparation method and application thereof

The application discloses a controllable release gallium-iron chelator composite nanohydrogel and a preparation method and application thereof. The nanohydrogel is formed by compounding gallium ions, iron chelators and a suitable polymer carrier, and can realize time and space controllable release. The nanohydrogel can first deplete the available iron of pathogens in an infection or inflammation microenvironment, induce the iron starvation response of the pathogens, and then slowly release gallium ions to simulate the role of iron, enter the pathogen cells and interfere with the iron-dependent metabolism, so as to synergistically play the roles of anti-infection and protection of host cells. The nanohydrogel can still maintain antibacterial activity in a high iron environment of pathogens through a double iron capture mechanism, and can inhibit iron-dependent cell death (such as ferroptosis) and inflammation cascade reaction of the host. The nanohydrogel has good biocompatibility, organ targeting and controllable release characteristics, can be prepared into a local drug preparation or a systemic delivery preparation, is suitable for prevention and / or treatment of diseases related to fungal or bacterial infection, and has a significant application prospect.
Owner:LIANGZHU LAB

A method for improving the accuracy of cell tracking in vivo using an iron chelator

The present application relates to a method for improving the accuracy of in vivo cell tracking using iron chelators, comprising the following steps: S1, preparing drug materials; S2, preparing animals and cells: preparing bone marrow cells, S3, removing free iron chelators in vivo 89 Zr and 68 Ga, S4, radiolabeling mesenchymal stem cells and bone marrow cells; S5, performing Micro-PET imaging: S6, performing Micro-PET imaging data processing and analysis: S7, in vitro biodistribution; S8, performing pharmacokinetic studies; S9, extracting hAlu genomic DNA and performing qPCR detection; S10, establishing a standard curve of cell number and cycle threshold; S11, performing absorbed dose estimation; S12, performing in vitro cell experiments; S13, final statistical analysis. The present application provides a method for improving the accuracy of in vivo cell tracking using iron chelators, which realizes the effect of removing free radioactive metal ions in vivo using iron chelators, and ensures the accuracy of in vivo tracking labeled cells.
Owner:JIANGSU INST OF NUCLEAR MEDICINE +1